CIK: 0001792206
Total reported value
$271.0M
Reporting period: 2026-03-31 · Number of holdings: 9
Foresite Capital Management V, LLC disclosed 9 holdings in its latest 13F filing for the period ending 2026-03-31, with total reported value of $271.0M and a quarterly turnover rate of 70.4%.
Browse other institutions with $100M to $1B AUMBrowse other institutions starting with "F"
Foresite Capital Management V, LLC's disclosed holdings carry a Herfindahl concentration index of 0.308 — mathematically equivalent to about 3 equally-sized positions, well below its 9 actual disclosed holdings. That gap points to a strategy built around a small core of high-conviction bets rather than broad diversification.
Position sizes vary widely across the portfolio (a coefficient of variation of 1.41), with a handful of outsized bets alongside many smaller positions.
Recent activity leans toward adding more aggressively to already-large existing positions than to newly initiated ones (a 15.2 percentage-point tilt) — a pattern consistent with a momentum-following approach.
Sector classification currently covers about 6% of this portfolio's disclosed value; the remainder includes holdings (e.g. unmapped tickers, options, or other security types) not yet covered by our sector mapping.
Add ALMS
+2.0% $73.5M
Trim IRON
+25.1% $168.9K
Trim LYEL
0.0% -$5.1M
Trim MAZE
-70.0% -$2.8M
Trim CGON
0.0% $26.3M
Add HIMS
+170.2% $6.5M
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | ALMS | Alumis INC | Stock-Other | 47.94% | +13.63% | +2.04% | |
| 2 | CGON | Cg Oncology INC | Stock-Other | 25.08% | -0.28% | — | |
| 3 | IRON | Disc Medicine INC | Stock-Other | 8.83% | -5.62% | +25.08% | |
| 4 | HIMS | Hims & Hers Health INC | Stock-Healthcare | 5.65% | +0.26% | +170.24% | |
| 5 | EIKN | Eikon Therapeutics INC | Stock-Other | 5.15% | +5.15% | NEW | |
| 6 | LYEL | Lyell Immunopharma INC | Stock-Other | 3.53% | -5.40% | — | |
| 7 | PHVS | Pharvaris N.V. | Stock-Other | 2.02% | +2.02% | NEW | |
| 8 | NRIX | Nurix Therapeutics INC | Stock-Other | 1.52% | +1.52% | NEW | |
| 9 | MAZE | Maze Therapeutics INC | Stock-Other | 0.29% | -1.88% | -69.98% |
Performance for Q3 2026
+10.9%
Performance Last 4 Quarters
+311.9%
Based on 86% of reported portfolio value with available pricing
| Period | Holdings | Total value | Stability | Top holdings |
|---|---|---|---|---|
| 2026-03-31 | 9 | $271.0M | 70 | |
| 2025-12-31 | 7 | $164.4M | 50 | |
| 2025-09-30 | 6 | $108.7M | 61 | |
| 2025-06-30 | 6 | $80.7M | 0 | |
| 2025-03-31 | 6 | $87.6M | 100 | |
| 2024-12-31 | 6 | $120.2M | 0 | |
| 2024-09-30 | 5 | $143.9M | 0 | |
| 2024-06-30 | 5 | $156.6M | 0 | |
| 2024-03-31 | 5 | $106.5M | 0 | |
| 2023-12-31 | 5 | $73.4M | 0 | |
| 2023-09-30 | 7 | $62.7M | 0 | |
| 2023-06-30 | 10 | $136.9M | 0 | |
| 2023-03-31 | 11 | $135.3M | 0 | |
| 2022-12-31 | 11 | $128.8M | 0 | |
| 2022-09-30 | 14 | $130.1M | 0 | |
| 2022-06-30 | 14 | $143.1M | 0 | |
| 2022-03-31 | 17 | $244.9M | 0 | |
| 2021-12-31 | 16 | $407.0M | 0 | |
| 2021-09-30 | 17 | $321.8M | 0 | |
| 2021-06-30 | 17 | $254.2M | 100 | |
| 2021-03-31 | 20 | $340.2M | 100 | |
| 2020-12-31 | 12 | $135.0M | 0 |
Foresite Capital Management V, LLC's most significant position changes for 2026-03-31: Sold out: Natera INC (NTRA); New buy: Eikon Therapeutics INC (EIKN); New buy: Pharvaris N.V. (PHVS); New buy: Nurix Therapeutics INC (NRIX); Add: Alumis INC (ALMS) — shares +2.04%.
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | ALMS | Alumis INC | +13.6% | +2.04% | Add |
| 2 | HIMS | Hims & Hers Health INC | +0.3% | +170.24% | Add |
| 3 | CGON | Cg Oncology INC | -0.3% | — | Unchanged |
| 4 | MAZE | Maze Therapeutics INC | -1.9% | -69.98% | Trim |
| 5 | LYEL | Lyell Immunopharma INC | -5.4% | — | Unchanged |
| 6 | IRON | Disc Medicine INC | -5.6% | +25.08% | Add |
| 7 | NTRA | Natera INC | — | EXIT | Sold out |
| 8 | EIKN | Eikon Therapeutics INC | — | NEW | New buy |
| 9 | PHVS | Pharvaris N.V. | — | NEW | New buy |
| 10 | NRIX | Nurix Therapeutics INC | — | NEW | New buy |
| Period | Filed | Type | EDGAR |
|---|---|---|---|
| 2026-03-31 | 2026-05-15 | 13F-HR | View on EDGAR |
| 2025-12-31 | 2026-02-17 | 13F-HR | View on EDGAR |
| 2025-09-30 | 2025-11-14 | 13F-HR | View on EDGAR |
| 2025-06-30 | 2025-08-12 | 13F-HR | View on EDGAR |
| 2025-03-31 | 2025-05-15 | 13F-HR | View on EDGAR |
| 2024-12-31 | 2025-02-14 | 13F-HR | View on EDGAR |
| 2024-09-30 | 2024-11-14 | 13F-HR | View on EDGAR |
| 2024-06-30 | 2024-08-13 | 13F-HR | View on EDGAR |
| 2024-03-31 | 2024-05-15 | 13F-HR | View on EDGAR |
| 2023-12-31 | 2024-02-13 | 13F-HR | View on EDGAR |
| 2023-09-30 | 2023-11-13 | 13F-HR | View on EDGAR |
| 2023-06-30 | 2023-08-11 | 13F-HR | View on EDGAR |
| 2023-03-31 | 2023-05-12 | 13F-HR | View on EDGAR |
| 2022-12-31 | 2023-02-13 | 13F-HR | View on EDGAR |
| 2022-09-30 | 2022-11-14 | 13F-HR | View on EDGAR |
| 2022-06-30 | 2022-08-12 | 13F-HR | View on EDGAR |
| 2022-03-31 | 2022-05-13 | 13F-HR | View on EDGAR |
| 2021-12-31 | 2022-02-11 | 13F-HR | View on EDGAR |
| 2021-09-30 | 2021-11-12 | 13F-HR | View on EDGAR |
| 2021-06-30 | 2021-08-16 | 13F-HR | View on EDGAR |
| 2021-03-31 | 2021-05-17 | 13F-HR | View on EDGAR |
| 2020-12-31 | 2021-02-16 | 13F-HR | View on EDGAR |
Institutions with a similar AUM
CIK 0001950591
Total reported value
$271.0M
51 stks
2026-03-31
AUM within 0.0% of this institution
CIK 0001803397
Total reported value
$270.9M
116 stks
2026-03-31
AUM within 0.0% of this institution
CIK 0001172036
Total reported value
$271.1M
123 stks
2026-03-31
AUM within 0.0% of this institution
Institutions with overlapping top holdings
CIK 0002013341
Total reported value
$460.3M
17 stks
2026-03-31
2 of the top 5 holdings overlap, including Cg Oncology INC
CIK 0000310158
Total reported value
$349.4M
14 stks
2026-03-31
1 of the top 5 holdings overlap, including Eikon Therapeutics INC
CIK 0001553936
Total reported value
$30.9M
4 stks
2025-09-30
Stale — no recent filing
1 of the top 5 holdings overlap, including Alumis INC